HT-100 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	3

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02525302 (ClinicalTrials.gov)	May 2015	18/7/2015	HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02	HT-100 Long-term Safety and Pharmacodynamics in Patients With DMD Who Have Completed Protocols HALO-DMD-01 and HALO-DMD-02	Duchenne Muscular Dystrophy	Drug: HT-100	Akashi Therapeutics	NULL	Terminated	6 Years	20 Years	Male	10	Phase 2	United States
2	NCT01978366 (ClinicalTrials.gov)	October 2013	31/10/2013	Open Label Extension Study of HT-100 in Patients With DMD	An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01	Duchenne Muscular Dystrophy	Drug: HT-100	Processa Pharmaceuticals	NULL	Terminated	6 Years	20 Years	Male	17	Phase 2	United States
3	NCT01847573 (ClinicalTrials.gov)	May 2013	2/5/2013	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy	A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: HT-100	Processa Pharmaceuticals	NULL	Terminated	6 Years	20 Years	Male	17	Phase 1/Phase 2	United States